The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Changhua site meets international regulatory standards for global medical applications
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
